Tvardi Therapeutics (NASDAQ: TVRD) announced the publication of preclinical data evaluating its STAT3 inhibitor TTI-101 in the International Journal of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE